Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders
Journal of Neuromuscular Diseases, ISSN: 2214-3602, Vol: 2, Issue: 2, Page: 113-117
2015
- 17Citations
- 13Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- CrossRef17
- 16
- Captures13
- Readers13
- 13
- Mentions1
- References1
- 1
Review Description
Recent years witnessed an exciting increase in the number of clinical trials for neuromuscular disorders, in particular for Duchenne Muscular Dystrophy and Spinal Muscle Atrophy. Given the high emotional impact of such developments for devastating diseases with an urgent medical need, it is particularly important to justify human trials on the basis of robust preclinical studies and to avoid a waste of hopes and of funds. This review focuses the discussion on the quality in the conduct clinically-oriented preclinical assessments in rare neuromuscular disease models and on the importance in reporting of preclinical confirmatory studies. Accordingly, it invites scientists, journal publishers and funding agencies to require quality standards to improve translatability of preclinical findings.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84962291478&origin=inward; http://dx.doi.org/10.3233/jnd-140067; http://www.ncbi.nlm.nih.gov/pubmed/27858730; http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JND-140067; https://journals.sagepub.com/doi/full/10.3233/JND-140067; https://dx.doi.org/10.3233/jnd-140067; https://content.iospress.com:443/articles/journal-of-neuromuscular-diseases/jnd140067
IOS Press
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know